Home Business AcelRx stock falls 18% following Q4 results (NASDAQ: ACRX)

AcelRx stock falls 18% following Q4 results (NASDAQ: ACRX)


Rolled newspaper with the headline Quarterly Results

Zerbor / iStock via Getty Images

AcelRx Pharmaceuticals (ACRX -14.2%) stock fell following its Q4 results.

Q4 total revenue declined to $ 2K, compared to $ 738K in Q4 2020.

The company said 8.96K units of opioid pain drug DSUVIA were sold in Q4 2021, compared to 3.71K units in Q3 2021, but it recognized only $ 2K in net revenues in Q4 due to a $ 0.3M reserve for potential returns related to a certain wholesale customer that bought product for the Department of Defense (DoD) in 2020.

The company noted that the DoD bought exclusively from a secondary wholesale customer instead of their primary wholesaler, and thus AcelRx recorded a reserve in the event this product is not ultimately sold to the DoD.

Combined R&D and SG&A expenses amounted to $ 6.9M, compared to $ 8.7M in Q4 2020.

Q4 net loss was – $ 7.92M, compared to – $ 8.92M in Q4 2020.


The company expects to submit two NDAs for its pre-filled syringe product candidates, pending outcome of FDA feedback that is expected in Q2, and the manufacturing of initial lots of nafamostat.

Quarterly combined R&D and SG&A expense is expected to be between $ 9M and $ 10M.

The company added that annual debt service is expected to be ~ $ 10M as it continues to pay down amounts outstanding under its senior debt facility that matures in June 2023.

Annual capital expenditures are expected to be $ 2M.

Previous articleUS consumer sentiment falls in early March as inflation worries mount By Reuters
Next articleStephen White joins EMPIRE as Chief Product Officer


Please enter your comment!
Please enter your name here